264 related articles for article (PubMed ID: 9723264)
1. Safety and efficacy of conversion from once daily Sandimmun to twice daily Neoral cyclosporine in renal allograft recipients.
Vathsala A; Lee WT; Lu YM; Woo KT
Transplant Proc; 1998 Aug; 30(5):1746-8. PubMed ID: 9723264
[No Abstract] [Full Text] [Related]
2. Cyclosporine pharmacokinetic profiles in stable renal allograft recipients converting from Sandimmun to Neoral.
Vathsala A; Lee WT; Jacob E; Woo KT
Transplant Proc; 1996 Jun; 28(3):1324-6. PubMed ID: 8658678
[No Abstract] [Full Text] [Related]
3. Conversion from conventional Sandimmun to Neoral therapy in stable renal transplant recipients.
Løkkegaard H; Asmundsson P; Clausen P; Dieperink H; Hansen JM; Heaf J; Jensen SB; Kornerup HJ; Madsen S; Pedersen EB; Poulsen JV; Rasmussen K
Transplant Proc; 1996 Aug; 28(4):2199-201. PubMed ID: 8769199
[No Abstract] [Full Text] [Related]
4. Pharmacokinetic study of twice vs thrice daily dosing of Sandimmun Neoral in pediatric renal transplant patients.
Papachristou F; Gakis D; Sotiriou I; Liatsis I; Takoudas D; Antoniadis A
Transplant Proc; 1998 Aug; 30(5):1988-90. PubMed ID: 9723363
[No Abstract] [Full Text] [Related]
5. Abbreviated kinetic profiles to estimate exposure to CyA in renal allograft recipients treated with Sandimmun-Neoral.
Serafinowicz A; Gaciong Z; Majchrzak J; Baczkowska T; Nowacka E; Gradowska L; Rowiński W; Lao M
Transplant Proc; 1997; 29(1-2):277-9. PubMed ID: 9122994
[No Abstract] [Full Text] [Related]
6. Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a Neoral-equivalent cyclosporine formulation, using a dose-adjusted method.
First MR; Weiskittel P; Shah M; Peddi VR; Canafax D; Schroeder TJ
Transplant Proc; 1998 Dec; 30(8):3955-7. PubMed ID: 9865260
[No Abstract] [Full Text] [Related]
7. Conversion from Sandimmune to Neoral in patients with stable renal allograft function: UHKL experience.
Goh BL; Jalil R; Koh SN; Chua CT; Tan SY
Transplant Proc; 1998 Nov; 30(7):3535-6. PubMed ID: 9838548
[No Abstract] [Full Text] [Related]
8. Conversion to cyclosporine microemulsion (Neoral) in stable renal transplant patients: results from a single center.
Cossu M; Satta R; Branca GF; Pala PG; Serra G; Satta RP; Sorba G
Transplant Proc; 1998 Aug; 30(5):1762-3. PubMed ID: 9723271
[No Abstract] [Full Text] [Related]
9. Sandimmun-to-Neoral conversion in stable pediatric kidney transplant recipients.
Kelles A; Herman J; Tjandra-Maga TB; Van Damme-Lombaerts R
Transplant Proc; 1998 Aug; 30(5):1995-6. PubMed ID: 9723366
[No Abstract] [Full Text] [Related]
10. Sandimmun and Neoral treatment: pharmacokinetics and kidney function in paediatric and adolescent renal transplant.
De Palma MT; Giordano M; Colella V; Palumbo F; De Nicolo VE; Caringella DA
Transplant Proc; 1998 Aug; 30(5):1677. PubMed ID: 9723239
[No Abstract] [Full Text] [Related]
11. Safety, tolerability, and pharmacokinetics of Sandimmun Neoral: conversion study in stable renal transplant recipients.
Tsang WK; Ho YW; Tong KL; Chan WH; Chan A
Transplant Proc; 1996 Jun; 28(3):1330-2. PubMed ID: 8658681
[No Abstract] [Full Text] [Related]
12. Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmun Neoral, in renal transplant patients.
Taesch S; Niese D
Transpl Int; 1994; 7 Suppl 1():S263-6. PubMed ID: 11271220
[TBL] [Abstract][Full Text] [Related]
13. Conversion to Sandimmun Neoral in stable renal transplant recipients over 1 year: hepatitis, liver dysfunction, dosing intervals, and therapeutic ranges.
Hsieh H; Chien YS; Hsu KT; Chung HM
Transplant Proc; 1998 Nov; 30(7):3552-4. PubMed ID: 9838555
[No Abstract] [Full Text] [Related]
14. Comparative pharmacokinetic study of neoral versus Sandimmun in Japanese stable renal allograft recipients.
Takahara S; Ohta K; Ohashi Y; Namii Y; Uchida K; Okuyama A; Kainuma H; Takagi H; Takahashi K; Morikawa H
Transplant Proc; 2001 Jun; 33(4):2541-4. PubMed ID: 11406243
[No Abstract] [Full Text] [Related]
15. Comparative pharmacokinetic study of Neoral vs Sandimmun in Japanese stable renal allograft recipients.
Takahara S; Ohta K; Ohashi Y; Namii Y; Uchida K; Okuyama A; Kainuma H; Takagi H; Takahashi K; Morikawa H
Transplant Proc; 1999 Nov; 31(7):3089-92. PubMed ID: 10610595
[No Abstract] [Full Text] [Related]
16. Case study: de novo application of Neoral in renal transplantation.
Kahan BD
Transplant Proc; 1996 Aug; 28(4):2189-91; discussion 2192, 2195. PubMed ID: 8769196
[No Abstract] [Full Text] [Related]
17. Neoral pharmacokinetics in cynomolgus monkeys: relation to efficacy in renal allografting.
Schuurman HJ; Hengy JC; Ringers J; Vonderscher J; Schuler W; Jonker M
Transplant Proc; 1996 Dec; 28(6):3142-4. PubMed ID: 8962218
[No Abstract] [Full Text] [Related]
18. The Swedish nationwide experience of converting transplant patients treated with Sandimmun to the new galenic formulation Sandimmun-neoral. The Swedish Sandimmun-Neoral Conversion Group.
Wilczek HE; Berglin E; Blohmé I; Bäckman L; Fehrman I; Källen R; Nyberg G; Säwe J; Wahlberg J
Transplant Proc; 1997; 29(1-2):280-3. PubMed ID: 9122995
[No Abstract] [Full Text] [Related]
19. A critical appraisal of cyclosporine A pharmacokinetics in pediatric kidney transplantation using a microemulsion galenic formulation (Neoral).
Foradori A; Pinto VM; Elberg A
Transplant Proc; 1998 Aug; 30(5):1666-7. PubMed ID: 9723235
[No Abstract] [Full Text] [Related]
20. Mass conversion from Sandimmun to Sandimmun Neoral: 1 1/2-year experience.
Huraib S; al Khudair W; Selim H; Iqbal A; Quadri K; Abu Romeh S; Chaballout A
Transplant Proc; 1997 Nov; 29(7):2980-2. PubMed ID: 9365637
[No Abstract] [Full Text] [Related]
[Next] [New Search]
